Always a pleasure to discuss #neuroendocrinetumos w friends from Argentina 🇦🇷Juan OConnor Instituto Alexander Fleming Hosp Udaondo 😊 A.C.Camargo Cancer Center

Meet our OncoDaily Party Barcelona Hosting Committee! 🎉 🚨🚨 Get ready for the ultimate night during #ESMO2024 ✌ Remember the epic vibes from #ASCO24? 😎🍹🥂🍸🏖🏝 Friday, September 13th, on the beautiful #Barcelona beach 💃🕺 It’s going to be an unforgettable party! 🤩 Want

Are you a #mentor seeking to learn more about how to inspire your mentees? Join the “Mentor the #mentor” session for guidance on how to better engage with your mentees at #ESMO24 on Saturday, 14 Sept at 11:45 in Tarragona Auditorium at #ESMO24. 📌 ow.ly/125N50TlV3h

#ESMO24 ESMO - Eur. Oncology Excellent discussion by Jenny Seligmann contextualizing IO in early stage #CRCsm NICHE-2 and NICHE-3 Myriam Chalabi & IMHOTEP 📌non-randomized datasets, robust and meaningful efficacy 📌higher pCR with more IO ✅is this data enough to change practice? YES ⛔️is

Thank you #ESMO2024 for the amazing speaker’s dinner - even more special in the company of Friends Jaume Capdevila Garcia-Carbonero's Lab Andres Cervantes

#ESMO2024 what an honor to be part of #neuroendocrinetumors educational session w amazing experts Garcia-Carbonero's Lab Simona Glasberg

Lower doses of everolimus similarly effective to standard dose in pts w #neuroendocrinetumors this set the basis for our EVENET trial (now open). NCT06472388 #ESMO2024 A.C.Camargo Cancer Center

#ESMO24 ESMO - Eur. Oncology CABINET - ph3 cabozantinib vs placebo in pre-treated advanced #Neuroendocrine NETs Alliance for Clinical Trials in Oncology NEJM Jennifer Chan 📌results presented by BICR for epNET and pNET ➡️ORR 5% vs 0 in epNET, 19% vs 0 in pNET ➡️PFS HR 0.38 in epNET, HR 0.23 in pNET OncoAlert OncologyEducation

Hot off the press, Alliance CABINET! Cabozantinib in previously treated (93% had SSA, 60% had PRRT, 72% had everolimus) advanced NETs. The primary endpoint, PFS, was significantly better in the cabo arm than placebo. Alliance for Clinical Trials in Oncology nejm.org/doi/full/10.10…

Can NET become NEC(-like)? The answer is yes according to: Rapid Evolution of Metastases in Patients with Treated G3 Neuroendocrine Tumors Associated with NEC-Like Transformation and TP53 Mutation | Endocrine Pathology (springer.com). NET + TP53 mutation 👉 NEC

Our syst rev on #TKI efficacy n safety in pts with #neuroendocrinetumors doi.org/10.1177/175883… Therapeutic Advances in Medical Oncology A.C.Camargo Cancer Center

Burnout and depression among physicians, a NEJM review nejm.org/doi/full/10.10… Srijan Sen #MedTwitter

🩺Editorial Review Board member Rodrigo G. Taboada and Assc. Editor Rachel Riechelmann were key contributors to this comprehensive analysis, advancing the understanding of TKIs in NET management. Read more about their insights and findings in the article: journals.sagepub.com/doi/epdf/10.11…

1st Latam #ASCO Workshop in Clinical Research in São Paulo 🇧🇷 talks on Drug Optimization Trials and early phase trials. Many drugs can be used with less doses/ frequency, offering similar efficacy , less tox and less cost. These trials should be highly encouraged!!

Rachel Riechelmann ASCO Innovation in drug optimization, particularly finding ways to achieve similar efficacy with lower doses or frequency, is a crucial step forward in the journey toward personalized medicine. Such approaches can result in significant benefits, not only in reducing potential side

Chromogranin A is NOT a screening test for neuroendocrine tumors. Chromogranin A is NOT a reliable tumor marker for monitoring disease (let alone making treatment decisions) among patients with neuroendocrine tumors. Chromogranin A CAN be falsely elevated due to causes such